Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CPHNASDAQ:CRONTSE:GUDNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHCipher PharmaceuticalsC$12.40-0.5%C$12.49C$8.01▼C$19.69C$222.62M1.233,013 shs23,119 shsCRONCronos Group$2.05+1.5%$1.86$1.60▼$2.66$790.08M1.061.31 million shs899,530 shsGUDKnight TherapeuticsC$5.75-0.2%C$5.85C$5.09▼C$6.45C$581.61M0.563,982 shs79,785 shsTLRYTilray$0.46+3.3%$0.50$0.41▼$2.15$467.62M1.9534.88 million shs16.72 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHCipher Pharmaceuticals-0.32%+2.98%+0.56%+2.38%+39.37%CRONCronos Group+1.00%-2.42%+10.38%+1.00%-24.63%GUDKnight Therapeutics-0.69%0.00%-2.70%+4.54%-2.87%TLRYTilray+1.44%+3.88%-5.70%-40.83%-75.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHCipher Pharmaceuticals1.2804 of 5 stars2.40.00.00.00.62.51.3CRONCronos Group1.8146 of 5 stars0.05.00.00.03.90.01.3GUDKnight TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray1.4374 of 5 stars3.11.00.00.01.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHCipher Pharmaceuticals 2.75Moderate BuyC$14.7518.95% UpsideCRONCronos Group 0.00N/AN/AN/AGUDKnight Therapeutics 3.50Strong BuyC$7.1524.35% UpsideTLRYTilray 2.25Hold$1.92312.54% UpsideCurrent Analyst Ratings BreakdownLatest CPH, CRON, GUD, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ BuyC$6.504/14/2025TLRYTilrayRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilrayPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.004/7/2025CPHCipher PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHoldC$12.503/25/2025GUDKnight TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuyC$6.25 ➝ C$7.453/21/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/11/2025GUDKnight TherapeuticsResearch CapitlSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHCipher PharmaceuticalsC$19.03M11.70C$3.51 per share3.53C$3.96 per share3.13CRONCronos Group$124.59M6.34N/AN/A$2.87 per share0.71GUDKnight TherapeuticsC$348.70M1.67C$1.49 per share3.85C$7.65 per share0.75TLRYTilray$210.48M2.22N/AN/A$4.14 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHCipher PharmaceuticalsC$11.41MC$0.9113.69∞N/A59.92%17.93%7.90%N/ACRONCronos Group-$73.96M$0.13N/A68.331.74-42.65%-2.56%-2.47%8/14/2025 (Estimated)GUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/ATLRYTilray-$244.98M-$1.05N/AN/AN/A-30.95%-4.40%-3.57%8/4/2025 (Estimated)Latest CPH, CRON, GUD, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million4/8/2025Q3 2025TLRYTilray-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHCipher PharmaceuticalsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ATLRYTilrayN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHCipher Pharmaceuticals41.222.002.67CRONCronos GroupN/A24.2423.05GUDKnight Therapeutics7.523.361.79TLRYTilray0.102.541.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHCipher Pharmaceuticals1.38%CRONCronos Group8.71%GUDKnight Therapeutics12.58%TLRYTilray9.35%Insider OwnershipCompanyInsider OwnershipCPHCipher Pharmaceuticals42.00%CRONCronos Group7.30%GUDKnight Therapeutics45.62%TLRYTilray0.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHCipher Pharmaceuticals517.95 millionN/ANot OptionableCRONCronos Group450385.41 million356.14 millionOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableTLRYTilray2,6501.01 billion929.50 millionOptionableCPH, CRON, GUD, and TLRY HeadlinesRecent News About These CompaniesWhy These Canadian Cannabis Stocks Deserve a Spot on Your WatchlistMay 29 at 10:00 AM | marijuanastocks.comSweetWater Brewing and Zoo Atlanta Celebrate 18 Years of Collaboration with a Special Edition BeerMay 29 at 8:00 AM | globenewswire.comTilray Brands to Present at TD Cowen's 9th Annual Future of the Consumer ConferenceMay 29 at 7:00 AM | globenewswire.comTilray (NASDAQ:TLRY) Stock Price Up 4.7% - Time to Buy?May 28 at 4:08 PM | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Down 2.2% - What's Next?May 24, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Trading 1.6% Higher - Should You Buy?May 23, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Trading Down 0.2% - Should You Sell?May 22, 2025 | marketbeat.comIntroducing Y'all's Beer: A True Taste of Texas from Revolver BrewingMay 22, 2025 | globenewswire.comTilray Medical Brings Canada's Iconic Cannabis Brand Good Supply to GermanyMay 22, 2025 | globenewswire.comTilray (NASDAQ:TLRY) Stock Price Up 1.5% - Still a Buy?May 21, 2025 | marketbeat.comTop Marijuana Stocks In A Volatile MarketMay 21, 2025 | marijuanastocks.comTilray (NASDAQ:TLRY) Shares Down 6.9% - Should You Sell?May 20, 2025 | marketbeat.comTidal Investments LLC Has $14.09 Million Position in Tilray Inc (NASDAQ:TLRY)May 20, 2025 | marketbeat.comTilray Brands (NasdaqGS:TLRY) Plans Reverse Stock SplitMay 17, 2025 | finance.yahoo.comTilray (NASDAQ:TLRY) Trading Up 4.5% - Time to Buy?May 17, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Shares Down 4.4% - Time to Sell?May 16, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Down 1.4% - Here's What HappenedMay 15, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Down 2.1% - Should You Sell?May 14, 2025 | marketbeat.comTilray Brands Announces the Launch of XMG Atomic Sours: New THC Beverages and EdiblesMay 14, 2025 | globenewswire.comTilray Inc (NASDAQ:TLRY) Shares Purchased by Dimensional Fund Advisors LPMay 14, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Up 1.2% - Here's WhyMay 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPH, CRON, GUD, and TLRY Company DescriptionsCipher Pharmaceuticals TSE:CPHC$12.40 -0.06 (-0.48%) As of 04:00 PM EasternCipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.Cronos Group NASDAQ:CRON$2.05 +0.03 (+1.49%) Closing price 04:00 PM EasternExtended Trading$2.04 0.00 (-0.24%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$5.75 -0.01 (-0.17%) As of 04:00 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Tilray NASDAQ:TLRY$0.46 +0.01 (+3.31%) Closing price 04:00 PM EasternExtended Trading$0.46 0.00 (-0.99%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
